Limited Medicare Drug Price Negotiation Placed into Reconciliation Bill; 340B Impact Unclear

U.S. Senate Majority Leader Chuck Schumer (D-N.Y.) announced on Tuesday that congressional Democrats and the White House reached agreement on federal drug pricing legislation. | C-SPAN

Democratic lawmakers have come to an agreement for placing a limited drug price negotiation plan for the Medicare program into the Build Back Better bill, but how it will impact the 340B program remains to be seen.

“By empowering Medicare

Read More »

Grassley Asks HHS General Counsel Nominee About Drug Companies “Harming Access” to 340B

HHS General Counsel nominee Sam Bagenstos answered questions about the 340B program during his Oct. 26 Senate Finance confirmation hearing.

A GOP U.S. Senator who has been active on 340B matters for decades last week asked President Biden’s pick to be the U.S. Health and Human Services Department’s top lawyer if HHS could be doing more to protect the 340B

Read More »

Democrats Still Trying to Make a Deal on Federal Drug Pricing Legislation

Congressional Democrats and the White House reportedly are still trying to strike a deal on federal drug pricing legislation.

Efforts to pass federal drug pricing legislation, pronounced dead by many last week, arose in time for Halloween.

Liberal and conservative congressional Democrats and the White House reportedly are still trying to strike a deal centered on letting Medicare negotiate

Read More »

340B Lobbying Intensifies on Capitol Hill and in Federal Agencies

2021 could be the runner up to 2018 in terms of 340B lobbying intensity, as measured by citations on lobbying disclosure forms.

2021 is on track to rival peak year 2018 in lobbying intensity on the 340B drug pricing program.

Attention on health care lobbying in Washington today focuses on the huge sums the drug industry is spending fighting Democratic drug price

Read More »

News Alert: Boehringer Ingelheim Sues HRSA in Defense of its 340B Contract Pharmacy Policy

Boehringer Ingelheim sued the federal government this afternoon in defense of its policy of denying hospitals 340B drug discounts when hospitals use contract pharmacies.

Drug manufacturer Boehringer Ingelheim (BI) sued the federal government this afternoon in federal district court in Washington, D.C., in defense of its policy of denying hospitals 340B drug discounts when hospitals use contract pharmacies.

BI is the seventh manufacturer to

Read More »

Senate Panel Backs Penalizing Drugmakers for their 340B Contract Pharmacy Actions

The Democratic-controlled Senate Appropriations Committee says it's pleased with HRSA's response to six drug manufacturers’ denials of 340B drug discounts involving contract pharmacy.

U.S. Senate appropriators say they’re happy with the federal government’s response to six drug manufacturers’ denials of 340B drug discounts involving contract pharmacy.

The Democratic-controlled Senate Appropriations Committee praised the U.S. Health Resources and Services Administration (HRSA) for its actions

Read More »

340B Report Publisher and CEO: If Congress Flips Next Year, Expect 340B To Get A Very Close Look

Ted Slafsky
If Congress changes hands during next year’s mid-term elections, expect a renewed effort to place significant restrictions on the 340B program, 340B Report Publisher and CEO Ted Slafsky predicts.

If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the spotlight with a renewed effort to place significant restrictions on the program, 340B Report Publisher and CEO Ted Slafsky writes

Read More »

Kalderos Sues HHS and HRSA, Says Ban on Drug Company Conditions on 340B Sales is Illegal

A mock-up of Request, one of the modules that make up Kalderos' 340B Pay service to enable drug manufacturers to provide 340B ceiling prices as rebates instead of as discounts.

Pharmaceutical industry vendor Kalderos has asked a federal court to vacate a federal health agency’s policy prohibiting drug manufacturers from conditioning 340B drug discounts on covered entities’ submission of drug claims data.

Kalderos has created a service called 340B

Read More »

Montana GOP Congressman Proposes a Host of New Conditions on 340B Hospitals

First-term U.S. Rep. Matt Rosendale (R-Mont.) has introduced a bill to impose a host of new conditions on hospital participation in the 340B drug discount program.

Montana’s at-large Republican U.S. congressman has introduced a bill to impose a host of new conditions on hospital participation in the 340B drug discount program.

First-term U.S. Rep. Matt Rosendale (R-Mont.) isn’t a member of the House Energy & Commerce

Read More »

Half of Congressional Black Caucus Asks CMS to End Medicare Drug Payment Cuts for 340B Hospitals

Reps. Robin Kelly (D-Ill.), left, and Lisa Blunt Rochester (D-Del.), right, led the Sept. 24 letter urging CMS to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.

Half of the Congressional Black Caucus (CBC) has asked Centers for Medicare & Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure to end the nearly 30% cut in Medicare Part B drug payments to 340B hospitals.

Reps. Robin Kelly (D-Ill.) and Lisa

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live